Introduction: Macrophage myofasciits is a rare cause of muscle pain related to aluminium hydroxide following intramuscular vaccinations. Small patient cohorts and case reports associate the condition with classical PAS-positive macrophages on biopsy. Here we present a challenging case of macrophage myofasciitis which was PAS-negative on biopsy and refractory to steroid reduction. The patient is now established on reducing oralcorticosteroids and subcutaneous methotrexate. Case description: A 63 year old retired commercial airline attendant presented in December 2017 with an abrupt onset of severe pain and stiffness in the calves, thighs, arms and shoulders with fevers and night sweats. There was no reported infectious prodrome. Past medical history included hypertension, hypercholesterolaemia, left shoulder arthroscopy and cholecystectomy. Regular medications included ramipril, bendroflumethiazide, atorvastatin, omperazole, ibuprofen and paracetamol. He had received multiple travel vaccines over several decades. Clinical examination on presentation revealed stiffness on mobilising and tender biceps, calves and thighs. Neurological examination was unremarkable. There was no rash, lymphadenopathy or peripheral synovitis. Cardiovascular, respiratory and abdominal examinations were unremarkable. Blood tests on presentation showed a CRP 85, ESR 50 and WBC 15 (neutrophilia). A working diagnosis of polymyalgia rheumatica was proposed with the need to exclude malignancy and occult infection. Cultures for blood and urine were negative. TFT's, PSA and urine EPS were negative. The patient was commenced on prednisolone 20mg once daily. One week after starting steroids there was a deterioration in symptoms with worsening muscle pains, fever, irritability, insomnia nocturnal pain and pleuritic chest pains. Blood testing revealed a further deterioration in acute phase markers (peak WCC 34,CRP 350 and ESR 85), with the presence of a hepatitis (peak ALT 180 , ALP 230 and GGT 600), hyperferritinemia (2600) and low albumin (22g/dl). CK levels remained normal and autoantibody testing was negative (ANA, ENA, RhF, anti-CCP, myositis panel, HMG CoA reductase ab negative). The patient had severe pain requiring high dose opioid analgesia (morphine), NSAIDs (celecoxib), IV paracetamol and nefopam to control pain. MRI of the thighs revealed bilateral myofascial oedema affecting the quadriceps and hamstring muscles. CT PET revealed high signal from the fascial areas. A subsequent myofascial muscle biopsy showed PAS negative macrophagic infiltration in the fascia and muscles. MRCP and ECHO were within normal limits. EMG showed myopathicchanges alone. A diagnosis of macrophage myofasciitis was made and the patient was treated with high dose prednisolone (60mg once daily). Over the following two weeks pain and stiffness slowly improved, which correlated with an improvement in inflammatory markers and liver function tests. Unfortunately prednisolone resulted in mood lability and insomnia. Analgesics were weaned to cessation and the patient was commenced on mycophenolate as a second line agent prior to discharge. Despite mycophenolate 1.25g twice daily, there was a relapse of limb pain, stiffness and inflammatory markers (CRP 55, WBC 15) on decreasing prednisolone to 30mg once daily. As liver function tests were near normal, mycophenolate was switched to subcutaneous methotrexate (20mg weekly) and prednisolone was successfully weaned to 10mg once daily. This resulted in normalisation of the inflammatory markers (CRP 7, ESR 10 and WBC 11) and resolution of pain and stiffness. Discussion: Macrophage myofasciitis is a rare inflammatory syndrome which typically affects middle aged adults and is characterised by the presence of aluminium hydroxide (Alum) crystals within macrophages at sites of previous intramuscular vaccinations, classically the left deltoid. Clinical presentation may occur up to 10 years after vaccination and includes arthro-myalgia, chronic fatigue and cognitive impairment. A study of 130 patients with a similar presentation and history of aluminiumcontaining vaccines showed that one third had biopsy proven macrophage myofasciitis. It isconsideredpartof the autoimmune/inflammatory syndrome induced adjuvants or ASIA spectrum of diseases. It has been associated with an increase in cytokines CCL2/MCP-1 levels compared to healthy subjects. Histopathology characteristically shows focal epi-, peri-and endomysial inflammatory infiltrate with PAS-positive macrophages and CD8þ T-cells. There is no significant muscle fibre injury. This case aims to raise awareness of this disease which must be included in the differential of patients presenting with inflammatory arthro-myalgias such as polymyalgia rheumatica and inflammatory myositis. MRI and PET-CT with targeted biopsy will lead to the diagnosis and methotrexate appears to be the DMARD of choice. Key Learning Points: Consider macrophage myofasciitis in cases of resistant PMR and inflammatory pain. MRI and PET-CT useful in establishing diagnosis with myofascial biopsy. Methotrexate is the drug of choice inthis single case.
FABRY DISEASE PRESENTING AS AUTOIMMUNE
Rheumatology, Guys and St Thomas NHS Trust, London, UNITED KINGDOM Introduction: Fabry disease is an X-linked lysosomal storage disorder caused by deficiency of galactosidase A activity resulting in accumulation of globotriaosylceramide and related glycosphingloipids. Progressive accumulation of glycosphingolipidsin the vascular endothelium results in ischaemia and infarction of small vessels due to vascular occlusion, with particularly damaging effect to the kidneys, heart and brain. Substantial deposition in podocytes leads to proteinuria, and in cardiomyocytes leads to cardiac hypertrophy and conduction abnormalities. Early clinical manifestations in childhood and adolescence include intermittent pain in the extremities (acroparesthesiae), angiokeratomas, corneal opacity, hypohidrosis, heat, cold and exercise intolerance, proteinuria, and gastrointestinal disturbance. By adulthood, patients may have developed end-stage renal failure and/or severe cardiac or cerebrovascular disease, although milder, atypical variants also exist that present later in life (>40 years) with cardiomegaly and mild proteinuria without any of the earlier symptoms. Males tend to have a more severe disease phenotype, although some heterozygotic females also exhibit severe disease due to random X-chromosomal inactivation. It is a rare condition with incidence estimates ranging from 1 in 40,000 to 60,000 males. Despite symptoms usually starting in childhood, they are often misattributedtootherconditions,especiallyinthe absence of afamily history when the average age of diagnosis is 29 years. The Fabry Outcome Survey of all consenting patients receiving or eligible for enzyme replacement therapy in Europe found that 25% were originally misdiagnosed, and 39% of misdiagnoses were rheumatological diseases. We describe two patients who received delayed diagnosis of their Fabry's disease but who appear to still have a genuine diagnosis of an autoimmune rheumatic disease alongside Fabrydisease. Case description: Patient A -Fabry disease with antiphospholipid syndrome Patient A was a previously healthy 47 year old female patient when she presented to A&E on multiple occasions with recurrent episodes of acute chest pain with elevated troponin and ECGs showing static T wave inversion in the lateral leads. Repeated coronary artery angiograms and an intra-vascular ultra-sound failed to show any significant coronary artery narrowings. Echocardiogram, V/Q scan and CTPA were all normal. She had a persitent tropinaemia with a normal CK and LDH. Further history elicited a background of four pregnancies, including a miscarriage at 10 weeks and a significant post-partum haemorrhage with another. She had arthralgia withearlymorningstiffness lastingonetotwohours,longstanding hair fall, and extreme fatigue. IgM anticardiolipin was positive and the lupus anticoagulant was strongly positive. Anti-nuclear antibody (ANA) was weakly positive in a nucleolar pattern (though subsequent tests have been negative). Crithidia dsDNA, Ro (SSA), La (SSB), RNP, Sm, Scl-70, Jo-1 and Ribosomal antibodies were not detected. Complement C3/C4 levels were normal. Cardiac MRI confirmed a mid-wall area of a late Gadolinium enhancement and a mild pericardial effusion -consistent with inflammatory perimyocarditis. The diagnosis was made of cardiac anti-phospholipid syndrome with inflammatory myocarditis. Despite mycophenolate and hydroxychloroquine immunosuppression, her symptoms persisted and a repeat cardiac MRI three years after starting mycophenolate, showed increased scar volume and evidence of ongoing inflammation. At this point a left ventricular biopsy was arranged which showed extensive myocyte vacuolisation, interstitial fibrosis and scarformation.Thesefindingsarenon-specificbutitwasfelttobeconsistent with hydroxychloroquine-induced cardiomyopathy, and her troponin and BNP levels did show improvement upon stopping hydroxychloroquine. Two years later, she has been troubled by runs of non-sustained ventricular tachycardia. A repeat MRI demonstrated left ventricular hypertrophy. At this point alpha galactosidase testing was performed and she was found to have a heterozygotic C644A-6 mutation in GLA gene consistent with Fabry disease. Immunosuppression has been stopped and she has now been started on enzyme replacement therapy. Warfarin can also be stopped as it is not indicated in purely obstetric anti-phospholipid syndrome, however the patient has chosen to continue this. Patient B-Fabrydisease with SLE and lupusnephritis Patient B is a 40 year old female. In 2001 she had a PE and DVT and a couple of years later developed a post-partum pericardial effusion with renal abnormalities identified at another hospital. She underwent a renal biopsy in 2003 which showed focal proliferative WHO class III lupus nephritis. The presence of Fabry-like cytoplasmic inclusions was also noted on the biopsy, although chloroquine toxicity was considered as a differential. Fabry disease was confirmed by a low alpha-galactosidase level and genetic testing revealed a heterozygote novel missense mutation in the GLA gene. She was diagnosed with SLE and managed with prednisolone, azathioprine and hydroxychloroquine. In 2010 she developed widespread lymphadenopathy, neutropenia, night sweats and fevers, and a fine needle aspirate of the lymph nodes demonstrated a reactive picture. Azathioprine was stopped due to the significant neutropenia. There wassomeinitial improvementinneutrophilcountfollowing increasing her steroid dose suggesting an autoimmune aetiology of her neutropenia, although ANA was negative at this time. She intermittently suffers from arthralgias, sweats and fevers, weight loss and lymphadenopathy. Subsequent ANA has been positive (up to 1:320 dilution) and further immunological testing supports the diagnosis of SLE with Anti-Ro, AntiC1q and dsDNA being present and C3 and C4 complement levels intermittently low. Lupus anticoagulant is positive but anticardiolipin antibodies are negative. In 2012 she developed chest pain on exertion. Resting ECG showed T wave inversion in lateral chest leads, I and aVL. A cardiac MRI showed extreme myocardial oedema and she underwent a left ventricular biopsy which did not demonstrate any inflammatory cell infiltration, complement or immunoglobulin deposition. In view of her SLE background she was managed as lupus myocarditis by increasing her prednisolone dose. Further immunosuppressants were not administered due to her persistently low neutrophil count (0.2) However, questions remain regarding whether the Fabry disease may be the underlying cause. A repeat cardiac MRI showed ongoing myocardial oedema with apical hypertrophic change with T2 enhancement suggesting Fabry disease. Ophthalmology review confirmed bilateral inferior episcleral microaneurysms consistent with Fabry disease. In 2013, she had a significant flare of her renal disease and repeat biopsy showed active Class III and Class V nephritis. Segmental sclerosing lesions were seen within the glomeruli which would be in keeping with either previous active lupus but also Anderson-Fabry disease given the presence of Fabry-type inclusions in swollen protocytes. On two separate occasions in 2017, she developed infected hair follicles alongside significant neutropenia. Following antibiotic therapy with GCSF she then developed a severe thrombocytopenia and which responded well to IVIg and she was started on mycophenolate mofetil (MMF). She currently remains stable on MMF from a renal, haematological and cardiac perspective and has not required anyenzyme replacementtherapy. Discussion: Fabry disease is multi-systemic and shares common symptoms with autoimmune rheumatic diseases, for example fatigue (62%) andneuropathicpain(77%).The co-existence ofFabrydiseaseandlupus nephritis histology on renal biopsy has previously been reported. It has also been shown that there is an increase in thrombotic tendency in Fabry patients (12%). Autoantibodies are commonly seen in Fabry disease. In a cohort of Argentinian Fabry disease patients, 57% patients showed reaction to at least one autoantibody (extractable nuclear antigen, doublestranded DNA, anticardiolipin or phosphatidylserine) with 45% patients having detectable anti-phospholipid antibodies. However, it is not clear how often these autoantibodies correlate with clinical sequelae specific to the connective tissue disease, rather than Fabry's, as they appear to in both our described cases. The high rate of prior misdiagnosis as rheumatological disease, may in reality reflect a high rate of co-morbidity with connective tissue disease. The abnormally deposited lipid products may act as an antigen to trigger the development of autoimmunity. Autoimmune diseases must therefore always be considered when reviewing patients with Fabry disease. Both patients also highlightthe difficulty of distinguishing Fabry pathology from autoimmune disease on biopsy. Myocyte enlargement due to perinuclear vacuolation and sarcoplasmic myelinoid bodies can be seen in ventricular biopsies of both Fabry disease or chloroquine toxicity. The presence of curvilinear bodies may help to distinguish cases of chloroquine toxicity. Fabry disease was diagnosed quickly in patient B because of the characteristic findings on kidney biopsy, however, patient A presented with Fabry disease affecting the heart which is less easily accessible to biopsy and subsequently her diagnosis was delayed by five years. Key Learning Points: Fabry disease and autoimmune rheumatic disease can co-exist and auto-antibodies are commonly found. Symptoms usually start in adolescence with intermittent acroparasthesiae, angiokeratomas, corneal opacity, hypohidrosis, heat, cold and exercise intolerance, proteinuria, and gastrointestinal disturbance. End-stage renal failure, severe cardiac or cerebrovascular disease are late manifestations of disease. Fabry disease is X-linked meaning females often present later with a milder phenotype. Enzyme replacement therapyisavailable butreliesonearly diagnosis. Introduction: We present a case of Noonan syndrome, which was diagnosed for the first time in a lady at the age of 50. She was referred to rheumatology for assessment of hypermobility, but was noted to have an unusual facies which triggered genetic testing. This case highlights the importance of comprehensive systems review and thorough clinical examination inpatients with hypermobility. Case description: A 50 year-old lady was referred for assessment of a possible hereditary connective tissue disease following a colonoscopy which found excessiveloopingin her colon. She hasknown hypermobility with associated biomechanical pain, diagnosed in another rheumatology unit in the past. She worked full time, was single and had no children. She was very active and held a black belt in kickboxing. However in the past five years, she had presented with multiple symptoms, culminating in 40 clinic appointments with eight medical and surgical specialties, physiotherapy and podiatry, as well as several emergency department attendances. Systemic enquiry revealed a multitude of symptoms including widespread musculoskeletal pain, constipation, thickened skin on her soles and easy bruising. Past medical history include convergent squint, narrow angle glaucoma, two corrective surgeries for ptosis aged 5 and 30, dilated pulmonary artery and pulmonary regurgitation and multiple trauma-relatedfractures.Onexamination,shewasnotedtohaveunusual facial features including ptosis, low set ears, thin eyebrows, thick curly hair and a short neck. She had a normal body mass index and a height of 167cm. She was hypermobile with a Beighton score of 6/9 and marked flexibility of the small joints of the hands. There was a mild scoliosis and an abnormally shaped chest wall. She had low arched feet with ankle pronation on standing and mild lymphoedema. She had high arched palate, extensible skin but no abnormal scars. Large bruises were noted on her legs. The initial clinical impression was that of a possible genetic collagen disorder, including rare forms of Ehlers Danlos syndrome. Genetic screening was arranged, which revealed an SOS1 mutation in keeping with Noonan syndrome. Discussion: Noonan syndrome is an autosomal dominant disorder with a prevalence of 1 in 1000 to 1 in 2500. Its clinical presentation changes with age. The musculoskeletal system can be affected, with features of small joint hypermobility and scoliosis. Our patient has a mild form of Noonan syndrome, which was only diagnosed at the age of 50. Yet, she exhibited typical clinical features of Noonan syndrome, including unusual facial appearance, small joint hypermobility, cardiac malformation, easy bruising, lymphoedema and ophthalmic manifestations. A number of these seemingly unrelated conditions, some of which may appear trivial in isolation, had been managed as single entities by a wide variety of health care professionals. Her unusual facial and musculoskeletal appearance, coupled by the collection of systemic manifestations, led to genetic testing and a unifying diagnosis. For the patient, this diagnosis was extremely important. She had always felt that she looked different, and now sheknew why. Key Learning Points: This case highlights the importance of careful and thorough clinical examination in all patients. In this case, the detection of subtle but unusual physical appearance led to a suspicion and eventually a diagnosis of a genetic disorder. Non-inflammatory, biomechanical musculoskeletal symptoms form a large proportion of new patient caseload in the general rheumatology clinic. Hypermobility, with or without associated musculoskeletal pain, is also increasingly recognised, reflected in increased referrals for its assessment to Rheumatology clinics. It is important for rheumatologist to be aware of the fact that hypermobility can be a feature of genetic disorders other than the commonly known Ehlers Danlos syndrome and Marfan syndrome. Having an open mind, and taking into account patients' symptoms which may not immediately appear relevant to the problem at hand can be helpful in joining the dots. Having a physician who is able to look at the whole picture, and provide a unifying explanation for their collection of ill-health, can be an extremely positive experience for the patient. 
